Pfizer’s investigational “ultra-long-acting” GLP-1 receptor agonist, PF-08653944, showed robust 12.3% weight loss in its Phase 2b VESPER-3 study. Transitioning from weekly to a once-monthly injection, the drug maintained high efficacy and tolerability, positioning Pfizer as a major competitor in the 2026 obesity drug market.
A landmark real-world analysis revealed that patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with Erleada® (apalutamide) saw a 51% lower risk of death compared to those treated with darolutamide. This data marks a significant breakthrough for patients seeking effective, “chemo-free” treatment options.
Eli Lilly and Company has announced a historic $3.5 billion investment to establish a state-of-the-art manufacturing campus in Fogelsville, Pennsylvania. As the largest life sciences project in the Commonwealth’s history, this facility will be dedicated to producing next-generation injectable medicines, including the investigational triple hormone receptor agonist retatrutide. The project is set to create 850 high-value jobs and solidify the Lehigh Valley as a premier global hub for pharmaceutical innovation and domestic supply chain resilience.
Johnson & Johnson announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending [Read More…]
Roche has announced robust 2025 results, reporting a 7% increase in Group sales (CER) and a massive 58% jump in IFRS net income. With 12 positive late-stage clinical readouts—including the promising obesity candidate CT-388—and a bullish 2026 forecast, the Swiss healthcare giant proves its resilience despite significant currency headwinds.
India’s Eyestem Research advances to Phase 2 clinical trials for Eyecyte-RPE™ following stellar Phase 1 results that showed significant vision restoration. As a scalable “off-the-shelf” solution for dry AMD, this therapy represents a major leap in regenerative medicine and a potential global cure for Geographic Atrophy.
Roche has unveiled breakthrough Phase II data for its obesity candidate, CT-388, showing a 22.5% reduction in body weight over 48 weeks. With nearly 73% of pre-diabetic patients returning to normal glucose levels, Roche is fast-tracking the drug into Phase III Enith trials to challenge the metabolic health market.
Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), has reported record-breaking financial results for the fourth quarter and full fiscal year [Read More…]
In a landmark development for personalized medicine, Moderna, Inc. and Merck (known as MSD outside the U.S. and Canada) announced today that their investigational mRNA-based [Read More…]
Abbott concludes 2025 with double-digit earnings growth and a powerful surge in Medical Device sales. With a new 2026 organic growth forecast of 6.5%–7.5% and a major entry into cancer diagnostics via the Exact Sciences acquisition, the healthcare leader signals a year of accelerated expansion ahead.
